Oncology Pipeline | Takeda Cancer Drug Development
Our Oncology Pipeline
Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody-drug conjugates (ADCs), complex biologics and small molecules. These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
Click + for additional information
Investigational therapy | Modality | Investigational indication | Phase | ||
Elritercept (TAK-226)† | |||||
Complex biologic | Second-line anemia-associated myelodysplastic syndromes | Phase 3 | |||
Complex biologic | Anemia-associated myelofibrosis | Phase 2 | |||
Mirvetuximab soravtansine-gynx (TAK-853) | |||||
ADC | Folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer (JP) | Phase 3 | |||
ADC | Folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (JP) | Phase 1/2 | |||
Rusfertide (TAK-121) | |||||
Small molecule | Polycythemia vera (USA) | Phase 3 | |||
TAK-168 | |||||
Small molecule | Solid tumors | Phase 1 |